Similar User
@AlpBugraBasat
@8thKingofRome
@DailyColateral
@Albatr055
@BacilUscus
@maddstone1
@BioPharmaMrkt
@atreat01
@Petereqqo
@briggs_raad
@chrisintroy
@HeliotropeRNA
@outremer511
@Milo10587755
$ADAP…..
$ADAP haha …yes the CEO has never played that card. It could change direction of the PPS….it has been declining almost continously for 3 years now…. -83%
Gugg Therapeutics Catalyst Tracker:" $ADAP will report a clinical update for lete-cel (NY-ESO-1 TCR) from the IGNYTE-ESO study (full pivotal trial analysis) in late 2024; $AMGN has a highly anticipated Phase II data readout for their obesity drug, AMG133 (GIPR/GLP1; MariTide) in…
Great targeted radiopharmaceuticals (TRT) landscape analysis from OPCO! A lot of people view this segment as the next ADC but so far it has been difficult to expand beyond SSTR2 and PSMA.
$ADAP It was a huge mistake to purchase alot of shares in the begining of the Year. The last many years has the trend been DOWN…. (Only short periods with increased pps.). There seem to be a never ending overall selling pressure….
$adap Its a start..
TCR cell therapies vanquish solid tumors — finally nature.com/articles/s4158…
🗞️WAR ON CANCER: FROM THE FRONTLINE Adaptimmune $ADAP has achieved FDA approval of afami-cel (Tecelra), the 1st engineered TCR-T cell therapy for solid tumors (synovial sarcoma) 🧐Why we think this is interesting: 👉🏼Solid tumors (90% of cancers) have been challenging to treat,…
7 Exercises That Will Fix Your Bad Posture:
This Advice will Change Your the Way you Look at this World (60 secs):
$ADAP they are back at it again, Will happen again and again and we see it higher before PDUFA , same plan for me... Check move in 2020 from 2 to 12 in 2 month Food for thought!
$ADAP after 60%+ move in a month it make sense for some ppl to take profit etc! but once that base there will be more backlog buyers and some dip buyers again imo! same plan holding till Aug Priority PDUFA!
The FDA is due to decide by 4th August whether to approve @Adaptimmune’s afami-cel engineered T-cell therapy for advanced #synovialsarcoma. $ADAP #oncology pharmaphorum.com/news/fda-sets-…
Is the best yet to come for cell therapy? I pulled together 45 companies in the space and charted the preclinical and clinical assets of each, segmented by cell source and modality Exhibit 1: Cell Therapy Landscape Some thoughts: The above is just a snapshot - an attempt to…
The biotech "simultaneous PRs" playbook has two options: 1. Positive data announcement, followed fast by financing announcement. 2. Negative data announcement, followed fast by restructuring/layoffs announcement.
Best Formulated #Biotech investor playbook - only when we break it - we can get back to serious $ibb $xbi #genetherapy #Immunotherapy investing $EDIT $VIR $BLUE $iova $rgnx $ALLO $nvta $adap $adpt $ENLV $sclx $IBRX $TAVT $omga $qure $DTIL
The biotech "simultaneous PRs" playbook has two options: 1. Positive data announcement, followed fast by financing announcement. 2. Negative data announcement, followed fast by restructuring/layoffs announcement.
$ADAP if they can get approval in Aug (with priority review) this is going to be awesome. Also if $IMCR gets taken out ADAP will be in spotlight. Also note: $IOVA ran from $3s to $9+ in anticipation of their PDUFA - check 3 months chart.
$ADAP noted it is less likely that there will be an AdComm given that the toxicity of afami-cel is lower than 1st-gen CAR-T. #JPM24
$AMAM ADC space continues en fuego run 🔥🔥🔥
After B7H4 $GSK does it again with Hansoh's B7H3 ADC 185m$ upfront+1.525bn$ biobucks+tiered royalties h/t @herbert_ou 🇨🇳ADCs are 🔥 🙂 x.com/herbert_ou/sta…
After B7H4 $GSK does it again with Hansoh's B7H3 ADC 185m$ upfront+1.525bn$ biobucks+tiered royalties h/t @herbert_ou 🇨🇳ADCs are 🔥 🙂 x.com/herbert_ou/sta…
Henson Pharmaceuticals (03692) announced licence agreement with GlaxoSmithKline for HS-20093 .The Product is a novel B7-H3 ADC) ,with initial payment of US$185 million and will be eligible to receive up to US$1,525 million in milestone payments @BertrandBio
$LLY's takeover of $PNT benefits more than just Point Biopharma, according to several analysts. $LNTH is partnered with Point on its two leading assets. $NVS is also working on radiological therapies. One analyst even says $AMAM could benefit because it's also working on a…
Coverage Initiated $AMAM: BTIG initiates at Buy - PT $26 $AUR: Evercore ISI initiates at In Line - PT $4 $BDN: KeyBanc initiates at Overweight - PT $6 $BGNE: Macquarie initiates at Outperform - PT $259 $BHLB: Seaport Global Securities initiates at Sell - PT $16 $BRKL: Seaport…
United States Trends
- 1. Cowboys 70,7 B posts
- 2. soobin 80,5 B posts
- 3. Clippers 11,5 B posts
- 4. Norman Powell 1.998 posts
- 5. Jerry 43 B posts
- 6. Texans 54,2 B posts
- 7. Cooper Rush 11,9 B posts
- 8. Mike McCarthy 3.269 posts
- 9. Sabrina 110 B posts
- 10. Joe Mixon 10,6 B posts
- 11. Lindy 3.674 posts
- 12. KADOKAWA 27,3 B posts
- 13. Trey Lance 3.211 posts
- 14. Dyson Daniels 2.821 posts
- 15. Herta 40,2 B posts
- 16. #AskShadow 7.334 posts
- 17. Keon Ellis 1.714 posts
- 18. #EeveeDay N/A
- 19. Eevee Evolution N/A
- 20. Harden 18,8 B posts
Who to follow
-
Alp Bugra Basat, MD
@AlpBugraBasat -
EM
@8thKingofRome -
Javi Cue
@DailyColateral -
Jeff Katz
@Albatr055 -
Bacil Uscus
@BacilUscus -
maddstone🇮🇱
@maddstone1 -
BioPharmaInvestor
@BioPharmaMrkt -
Jairus 'AJ' Treat
@atreat01 -
juventino32
@Petereqqo -
Briggs Raad
@briggs_raad -
Chris Tuttle
@chrisintroy -
Heliotrope
@HeliotropeRNA -
Gear
@outremer511 -
Milo
@Milo10587755
Something went wrong.
Something went wrong.